Patents by Inventor Douglas H. Smith
Douglas H. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124582Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.Type: ApplicationFiled: November 21, 2023Publication date: April 18, 2024Inventors: Ross LA MOTTE-MOHS, Kalpana SHAH, Douglas H. SMITH, Leslie S. JOHNSON, Paul A. MOORE, Ezio BONVINI, Scott KOENIG
-
Patent number: 11858991Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.Type: GrantFiled: January 12, 2021Date of Patent: January 2, 2024Assignee: MacroGenics, Inc.Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Publication number: 20230357404Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1 : PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mA.b 5, PD-1 mA.b 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1 -binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1 -binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.Type: ApplicationFiled: February 24, 2023Publication date: November 9, 2023Applicant: MACROGENICS, INC.Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Patent number: 11623959Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.Type: GrantFiled: January 24, 2020Date of Patent: April 11, 2023Assignee: MACROGENICS, INC.Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Publication number: 20210393960Abstract: In one aspect, the invention comprises an implantable living electrode comprising a substantially cylindrical extracellular matrix core; one or more neurons implanted along or within the substantially cylindrical extracellular matrix core, the one or more neurons including one or more optogenetic or magnetogenetic neurons proximal to a first end of the implantable living electrode.Type: ApplicationFiled: June 25, 2021Publication date: December 23, 2021Inventors: Daniel Kacy Cullen, James P. Harris, John A. Wolf, Han-Chiao Isaac Chen, Douglas H. Smith, Mijail Serruya
-
Patent number: 11072653Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.Type: GrantFiled: June 7, 2016Date of Patent: July 27, 2021Assignee: MacroGenics, Inc.Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Publication number: 20210206851Abstract: The present invention is directed to the anti-LAG-3 antibodies: LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunoconjugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cell. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.Type: ApplicationFiled: January 12, 2021Publication date: July 8, 2021Applicant: MacroGenics, Inc.Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Patent number: 10955004Abstract: A bearing cage is formed from a single piece of wire bent into shape and includes a first axial end ring, a second axial end ring including a distal end of the single piece of wire, a plurality of axially-extending bridge portions between the first and second axial end rings, and a plurality of circumferentially-extending connection portions interconnecting adjacent bridge portions. The connection portions are alternately positioned adjacent the first and second axial end rings.Type: GrantFiled: October 9, 2019Date of Patent: March 23, 2021Assignee: The Timken CompanyInventors: Rahul Chaudhari, Robert Ringle, Douglas H. Smith
-
Publication number: 20210003174Abstract: A bearing cage is formed from a single piece of wire bent into shape and includes a first axial end ring, a second axial end ring including a distal end of the single piece of wire, a plurality of axially-extending bridge portions between the first and second axial end rings, and a plurality of circumferentially-extending connection portions interconnecting adjacent bridge portions. The connection portions are alternately positioned adjacent the first and second axial end rings.Type: ApplicationFiled: October 9, 2019Publication date: January 7, 2021Inventors: Rahul Chaudhari, Robert Ringle, Douglas H. Smith
-
Publication number: 20200231675Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.Type: ApplicationFiled: January 24, 2020Publication date: July 23, 2020Applicant: MACROGENICS, INCInventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Patent number: 10577422Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.Type: GrantFiled: July 28, 2016Date of Patent: March 3, 2020Assignee: Macrogenics, Inc.Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Patent number: 10525085Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.Type: GrantFiled: January 5, 2018Date of Patent: January 7, 2020Assignee: The Trustees of the University of PennsylvaniaInventors: Douglas H. Smith, Daniel Kacy Cullen, John A. Wolf
-
Publication number: 20190126043Abstract: In one aspect, the invention comprises an implantable living electrode comprising a substantially cylindrical extracellular matrix core; one or more neurons implanted along or within the substantially cylindrical extracellular matrix core, the one or more neurons including one or more optogenetic or magnetogenetic neurons proximal to a first end of the implantable living electrode.Type: ApplicationFiled: April 14, 2017Publication date: May 2, 2019Inventors: Daniel Kacy Cullen, James P. Harris, John A. Wolf, H. Isaac Chen, Douglas H. Smith, Mijail Serruya
-
Publication number: 20190127467Abstract: The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.Type: ApplicationFiled: July 28, 2016Publication date: May 2, 2019Applicant: MacroGenics, Inc.Inventors: Kalpana Shah, Douglas H. Smith, Ross La Motte-Mohs, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Publication number: 20190085075Abstract: The present invention is directed to the anti-LAG-3 antibodies, LAG-3 mAb 1, LAG-3 mAb 2, LAG-3 mAb 4, LAG-3 mAb 5, and LAG-3 mAb 6, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to LAG-3-binding molecules that comprise LAG-3 binding fragments of such anti-LAG-3 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such LAG-3-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of detecting LAG-3, as well as methods of using molecules that bind LAG-3 for stimulating immune responses.Type: ApplicationFiled: June 7, 2016Publication date: March 21, 2019Applicant: MacroGenics, Inc.Inventors: Ross La Motte-Mohs, Kalpana Shah, Douglas H. Smith, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini, Scott Koenig
-
Publication number: 20180214492Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.Type: ApplicationFiled: January 5, 2018Publication date: August 2, 2018Inventors: Douglas H. SMITH, Daniel Kacy CULLEN, John A. WOLF
-
Patent number: 9895399Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.Type: GrantFiled: January 31, 2014Date of Patent: February 20, 2018Assignee: The Trustees of the University of PennsylvaniaInventors: Douglas H. Smith, Kacy D. Cullen, John A. Wolf
-
Publication number: 20160250385Abstract: The present invention provides compositions and methods for modulation of neuronal networks in the CNS and/or PNS. In certain embodiments, the invention includes modulation of existing networks or restoring one or more damaged or lost axonal connections. In one embodiment, the invention comprises a tissue-engineered composition comprising an elongated tubular construct having at least one neuron and axon extending through the core of the construct.Type: ApplicationFiled: November 3, 2014Publication date: September 1, 2016Inventors: D. Kacy CULLEN, Douglas H. SMITH
-
Publication number: 20160160282Abstract: The invention relates to methods of diagnosing risk of amyloid ? deposition following traumatic brain injury. The invention further relates to the discovery of a specific single nucleotide polymorphism in the neprilysin gene that is linked to an increased risk of amyloid ? deposition after traumatic brain injury.Type: ApplicationFiled: February 2, 2016Publication date: June 9, 2016Inventors: Douglas H. SMITH, William STEWART, Victoria E. JOHNSON
-
Publication number: 20150352153Abstract: The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury.Type: ApplicationFiled: January 31, 2014Publication date: December 10, 2015Inventors: Douglas H. Smith, Kacy D. Cullen, John A. Wolf